Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis
I'm LongbridgeAI, I can summarize articles.Johnson & Johnson reported long-term Phase 3 data for Icotyde (icotrokinra) in plaque psoriasis. The ICONIC-LEAD study showed sustained efficacy from week 64 to 112, with over 72% achieving PASI 90 and over 70% reaching clear or almost clear skin. Additionally, more than 44% achieved complete clearance (PASI 100), and improvements in itch were observed.
Key points:
- New phase 3 data found that plaque psoriasis patients treated with Johnson & Johnson's Icotyde (icotrokinra) saw high levels of skin clearance after more than two years of treatment.
- In the phase 3 placebo-controlled ICONIC-LEAD study, ≥72% of those on the oral IL-23 receptor agonist achieved a Psoriasis Area and Severity Index score (PASI) of 90 and ≥70% achieved clear or almost clear skin (Investigator's Global Assessment [IGA] 0/1) from week 64 through week 112.
- In addition, complete skin clearance continued from week 64 through week 112, as ≥44% of Icotyde reached PASI 100 and ≥46% achieving IGA 0 (clear skin).
- Improvements in itch were also seen from week 64 through week 112.
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.